Company Overview and News

10
U.S. Grants Emmanuelle Charpentier, U of C and University of Vienna CRISPR Patent

54m biospace
The U.S. Patent and Trademark Office (USPTO) granted Emmanuelle Charpentier, co-founder of ERS Genomics, the University of California and University of Vienna, their first U.S. patent covering the use of CRISPR/Cas9 for gene editing.
CRSP

97
Amgen Gets EU Nod to Add Survival Data on Blincyto's Label

2h zacks
Biotech major Amgen Inc. (AMGN - Free Report) announced that it has received European Commission’s (EC) approval to include overall survival (OS) data from the TOWER study on the label of its BiTE antibody, Blincyto.
PFZ AMGN CRSP 500680 PFE PFIZER GHDX

11
UCal and Partners Win U.S. Patent Related to CRISPR-Cas9

3h genengnews
The Regents of the University of California (UC), the University of Vienna, and Emmanuelle Charpentier, Ph.D., of the Max-Planck Institute in Berlin, have been granted U.S. Patent No. 10,000,772 for intellectual property related to CRISPR/Cas9 genome editing technology. [Genetic Literacy Project]
NTLA CRSP

11
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing

2018-06-19 globenewswire
ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Caribou Biosciences, Inc., announced that The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, Ph.D. (collectively, “UC”), co-owners of foundational intellectual property relating to CRISPR/Cas9 genome editing technology, were granted U.
NTLA VRTX CRSP

27
Top Stock Picks for the Week of June 18, 2018

2018-06-18 zacks
Occidental Petroleum (OXY - Free Report) is a large cap E&P which also has a chemical business. While it’s considered a more conservative play on the crude rebound because of its size, investors also get solid management and a dividend still yielding 3.7% even though the stock has rebounded off the 2017 lows. This Zacks Rank #1 (Strong Buy) is expected to see earnings jump an incredible 389% in 2018 as crude prices rise.
HD IP INPAP CRSP ZBRA OXY

81
Gilead Oncology CAR T-Cell Therapies Outlook Compelling

2018-06-18 seekingalpha
If cell therapies are curative, new business models will become more cyclical. Harvoni and Sovaldi cure rates exceeding 90% show Gilead understands this new paradigm.
VYGR BOLD NTLA ATRA EDIT GILD CRSP ABEO ABEOW ONCE

26
Think Twice Before Divesting In Crispr Amid Cancer Concerns

2018-06-15 seekingalpha
Two publications released Monday morning suggest CRISPR-Cas9 editing may lead to systematic propagation of cancer-prone cells.
NTLA EDIT CRSP

61
BioMarin Begins Pediatric Study on Achondroplasia Candidate

2018-06-15 zacks
BioMarin Pharmaceutical Inc (BMRN - Free Report) stated that it has dosed the first participant in a phase II study, evaluating its pipeline candidate, vosoritide, in pediatric patients with achondroplasia, a genetic disorder causing dwarfism in infants and toddlers.
SPG.PRJ CRSP SPG ENL BMRN ENDP

481
Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up

2018-06-13 seekingalpha
Tetraphase Pharma (TTPH) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; they also have a Qualified Infectious Disease Product (‘QIDP) for the drug candidate.
NTLA MKGAF OPK RCUS CORV ENL AQXP CUR EDIT ALXN AGN ADXS PFNX GTBP AMGN VTGN CRSP MDWD LLY SNY VICL LIVN MKGAY LIVN ENDP

40
How to Play the New Hawkish Fed

2018-06-13 zacks
The FOMC is poised to raise the Fed funds target rate by a quarter point in about an hour. And this is with over 95% certainty as this morning's PPI inflation data came in hotter than expected.
LRCX HUSV FGB CNC FCM CRSP HDMV ZBRA FOVCX FEO EW

112
Idera Stock Down, Study on Dermatomyositis Candidate Fails

2018-06-13 zacks
Idera Pharmaceuticals Inc (IDRA - Free Report) announced that the phase II clinical study, evaluating its pipeline candidate, IMO-8400, for dermatomyositis — a rare inflammatory skin disease — fell short of meeting the primary endpoint.
IDRAW IDRA CRSP GHDX BCRX

10
2 Studies: CRISPR Potentially Linked to Cancer Risk

2018-06-13 biospace
CRISPR-Cas9 is a fairly new technique to simply and quickly edited the genome. Its development launched a new era of genetics research and therapy development. Last summer, a paper published in Nature Methods found that the technique caused unexpected mutations throughout the genome. That has been retracted. Another study found some individual’s immune systems attacked Cas9, but researchers apparently feel that’s manageable.
CRSP

25
Crispr Therapeutics Down On Cancer Concerns - Unjustified Market Reaction?

2018-06-12 seekingalpha
Two reports in Nature and one interpretation of a STAT News report have taken the three CRISPR stocks down.
NTLA EDIT CRSP

52
Axon Enterprise Inc Stock Definitely Needs a Cooling off Period

2018-06-11 investorplace
Shares of Axon Enterprise Inc (NASDAQ:AAXN) fell 6.4% on Thursday after an analyst downgrade. But for obvious reasons, there’s no need to panic when it comes to Axon stock.
LMT MDGL JPM RTN CRSP I AAXN

11
Is CRISPR in Touble After New STAT Report?

2018-06-11 247wallst
CRISPR Therapeutics AG (NASDAQ: CRSP) shares tumbled Monday after a report was released that gene-edited cells might cause cancer. The implications of this study could be catastrophic for the company seeing as CRISPR is known for its gene-editing platform CRISPR/CAS9.
CRSP

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: H17182108